cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Celcuity Inc
3 own
2 watching
Current Price
$17.24
$0.85
(5.19%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
322.25M
52-Week High
52-Week High
22.18800
52-Week Low
52-Week Low
8.38900
Average Volume
Average Volume
0.22M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization322.25M
icon52-Week High22.18800
icon52-Week Low8.38900
iconAverage Volume0.22M
iconDividend Yield--
iconP/E Ratio--
What does the Celcuity Inc do?
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company s CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More
How much money does Celcuity Inc make?
News & Events about Celcuity Inc.
Accesswire
10 months ago
MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual...
Accesswire
1 year ago
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational statusMINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasdaq:CELC...
Accesswire
1 year ago
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference.Brian Sullivan, Chairman, Chief...
TipRanks Financial Blog
1 year ago
Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst Alexander Nowak on March 21. The companys share... Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst...
Frequently Asked Questions
Frequently Asked Questions
What is Celcuity Inc share price today?
plus_minus_icon
Can Indians buy Celcuity Inc shares?
plus_minus_icon
How can I buy Celcuity Inc shares from India?
plus_minus_icon
Can Fractional shares of Celcuity Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Celcuity Inc stocks?
plus_minus_icon
What is today’s traded volume of Celcuity Inc?
plus_minus_icon
What is today’s market capitalisation of Celcuity Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Celcuity Inc?
plus_minus_icon
What percentage is Celcuity Inc down from its 52-Week High?
plus_minus_icon
What percentage is Celcuity Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$17.24
$0.85
(5.19%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00